Multiparametric 3T endorectal MRI after external beam radiation therapy for prostate cancer

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 2, 2012, Pages 430-437

  Westphalen, Antonio C ^a   Reed, Galen D ^a   Vinh, Phillip P ^a   Sotto, Christopher ^a   Vigneron, Daniel B ^a   Kurhanewicz, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

diffusion MRI; MR spectroscopy; MRI; prostate cancer; radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; T2 WEIGHTED NUCLEAR MAGNETIC RESONANCE IMAGING;

AGED; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RECTUM; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84864253724     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23672     Document Type: Article

References (31)

1. American Cancer Society. Cancer facts and figures 2011. Atlanta: American Cancer Society: 2011.
2. Cooperberg M, Broering J, Carroll P,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117.
3. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57: 915-928. (Pubitemid 37324109)
4. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-2504.
5. Roehl KA, Antenor JA, Catalona WJ,. Serial biopsy results in prostate cancer screening study. J Urol 2002; 167: 2435-2439. (Pubitemid 34533140)
6. Stewart CS, Leibovich BC, Weaver AL, Lieber MM,. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86-91; discussion 91-82. (Pubitemid 32565349)
7. Chan TW, Kressel HY,. Prostate and seminal vesicles after irradiation: MR appearance. J Magn Reson Imaging 1991; 1: 503-511.
8. Sugimura K, Carrington BM, Quivey JM, Hricak H,. Postirradiation changes in the pelvis: assessment with MR imaging. Radiology 1990; 175: 805-813. (Pubitemid 20191950)
9. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 425-430.
10. Kim CK, Park BK, Lee HM,. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009; 29: 391-397.
11. Pucar D, Shukla-Dave A, Hricak H, et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005; 236: 545-553. (Pubitemid 41023438)
12. Westphalen AC, Coakley FV, Roach M 3rd, McCulloch CE, Kurhanewicz J,. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 2010; 256: 485-492.
13. Choi JY, Kim MJ, Chung YE, et al. Abdominal applications of 3.0-T MR imaging: comparative review versus a 1.5-T system. Radiographics 2008; 28: e30.
14. Song I, Kim CK, Park BK, Park W,. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol 2010; 194: W477-482.
15. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-974.
16. Chen AP, Cunningham CH, Kurhanewicz J, et al. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 2006; 24: 825-832. (Pubitemid 44205376)
17. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA,. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009; 30: 327-334.
18. deSouza NM, Riches SF, Vanas NJ, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008; 63: 774-782.
19. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW,. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging 2006; 23: 130-134. (Pubitemid 43191065)
20. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005; 21: 258-262. (Pubitemid 40280120)
21. Pickett B, Kurhanewicz J, Weinberg V, Pouliot J, Shinohara K, Roach M,. Magnetic resonance spectroscopy imaging and PSA responses following three-dimensional conformal external beam radiotherapy (3DCRT) or 3DCRT plus permanent prostate implant (PPI) for intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2005; 63 (Suppl 1): S142-172.
22. Pickett B, Ten Haken RK, Kurhanewicz J, et al. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2004; 59: 665-673. (Pubitemid 38748731)
23. Roach M, 3rd, Kurhanewicz J, Carroll P,. Spectroscopy in prostate cancer: hope or hype? Oncology 2001; 15: 1399-1410; discussion 1415-1396, 1418. (Pubitemid 33739250)
24. Kestin LL, Goldstein NS, Vicini FA, et al. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54: 107-118.
25. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M,. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48: 355-367.
26. Liang KY, Zeger SL,. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
27. Davison A, Hinkley D,. Confidence intervals. In: Bootstrap methods and their application, Cambridge series in statistical and probabilistic mathematics. Cambridge, UK: Cambridge University Press; 1997. p 191-251.
28. Westphalen AC, Kurhanewicz J, Cunha RM, et al. T2-weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol 2009; 35: 171-180; discussion 181-172.
29. Noworolski SM, Crane JC, Vigneron DB, Kurhanewicz J,. A clinical comparison of rigid and inflatable endorectal-coil probes for MRI and 3D MR spectroscopic imaging (MRSI) of the prostate. J Magn Reson Imaging 2008; 27: 1077-1082. (Pubitemid 351614619)
30. Rouviere O, Valette O, Grivolat S, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumorâcorrelation with biopsy findings. Urology 2004; 63: 922-927. (Pubitemid 38596680)
31. Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011; 21: 1970-1978.